Patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) may still be at risk for major cardiovascular (CV) events, despite taking medications consistent with guideline recommendations. Dr. Becker and Dr. Lee are here to share their perspectives on managing patients with chronic CAD/PAD who are at risk for CV events. They will also discuss the efficacy and safety results of the pivotal COMPASS trial and provide clinical guidance for deciding who should be considered for treatment with XARELTO® (rivaroxaban) 2.5 mg twice daily in combination with low-dose aspirin 75 mg to 100 mg once daily.